Metabonomic study of chronic heart failure and effects of Chinese herbal decoction in rats

Journal of Chromatography A

Volumn 1362, Issue , 2014, Pages 89-101

  Guo, Na ^a   Yang, Dawei ^b   Wang, Xiaoxing ^c   Dai, Jingang ^a   Wang, Mei ^d   Lei, Yan ^a  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b LIAOCHENG UNIVERSITY   (China)

^c CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^d Sino Dutch Centre for Preventive and Personalized Medicine   (Netherlands)

Author keywords

Chronic heart failure; Metabonomic; Shenfu decoction; UPLC TOF MS

Indexed keywords

BIOMARKERS; CARDIOLOGY; METABOLISM; METABOLITES; RATS;

CHRONIC HEART FAILURES; DYNAMIC TRAJECTORIES; METABONOMICS; MYOCARDIAL INFARCTION; SHENFU DECOCTION; THERAPEUTIC EFFICACY; TRADITIONAL CHINESE MEDICINE; UPLC/TOF-MS;

FAILURE (MECHANICAL);

BIOLOGICAL MARKER; CHINESE DRUG; HERBACEOUS AGENT; SHENFU DECOCTION; UNCLASSIFIED DRUG; SHEN-FU;

ACONITE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ECHOCARDIOGRAPHY; GINSENG; HEART FAILURE; HEMODYNAMICS; MALE; METABOLITE; METABOLOMICS; NONHUMAN; PRINCIPAL COMPONENT ANALYSIS; RAT; TIME OF FLIGHT MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; URINALYSIS; ANIMAL; CHRONIC DISEASE; ELECTROSPRAY MASS SPECTROMETRY; METABOLISM; PROCEDURES; REPRODUCIBILITY; SPRAGUE DAWLEY RAT;

ANIMALS; BIOLOGICAL MARKERS; CHRONIC DISEASE; DRUGS, CHINESE HERBAL; HEART FAILURE; MALE; METABOLOMICS; PRINCIPAL COMPONENT ANALYSIS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 84908563379     PISSN: 00219673     EISSN: 18733778     Source Type: Journal    
DOI: 10.1016/j.chroma.2014.08.028     Document Type: Article

References (48)

1. Remme W., Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur. Heart J. 2001, 22:1527-1560.
2. Doenst T., Nguyen T.D., Abel E.D. Cardiac metabolism in heart failure implications beyond ATP production. Circ. Res. 2013, 113:709-724.
3. Alagiakrishnan K., Banach M., Jones L.G., Ahmed A., Aronow W.S. Medication management of chronic heart failure in older adults. Drugs Aging 2013, 30:765-782.
4. Fu S., Zhang J., Menniti-Ippolito F., Gao X., Galeotti F., Massari M., Hu L., Zhang B., Ferrelli R., Fauci A. Huangqi injection (a traditional Chinese patent medicine) for chronic heart failure: a systematic review. PLoS ONE 2011, 6:e19604.
5. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 2000, 342:145-153.
6. López-Sendó J., Swedberg K., McMurray J., Tamargo J., Maggioni A.P., Dargie H., Tendera M., Waagstein F., Kjekshus J., Lechat P. Expert consensus document on β-adrenergic receptor blockers The Task Force on Beta-Blockers of the European Society of Cardiology. Eur. Heart J. 2004, 25:1341-1362.
7. Costanzo M.R., Guglin M.E., Saltzberg M.T., Jessup M.L., Bart B.A., Teerlink J.R., Jaski B.E., Fang J.C., Feller E.D., Haas G.J. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J. Am. Coll. Cardiol. 2007, 49:675-683.
8. Parang P., Singh B., Arora R. Metabolic modulators for chronic cardiac ischemia. J. Cardiovasc. Pharmacol. Ther. 2005, 10:217-223.
9. Wang L., Zhou G.B., Liu P., Song J.H., Liang Y., Yan X.J., Xu F., Wang B.S., Mao J.H., Shen Z.X. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:4826-4831.
10. Zimmermann G.R., Lehar J., Keith C.T. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today 2007, 12:34-42.
11. Guo N., Liu M., Yang D., Huang Y., Niu X., Wu R., Liu Y., Ma G., Dou D. Quantitative LC-MS/MS analysis of seven ginsenosides and three aconitum alkaloids in Shen-Fu decoction. Chem. Cent. J. 2013, 7:165.
12. Liang X., Chen X., Liang Q., Zhang H., Hu P., Wang Y., Luo G. Metabonomic study of Chinese medicine Shuanglong formula as an effective treatment for myocardial infarction in rats. J. Proteome Res. 2010, 10:790.
13. Tan G., Liao W., Dong X., Yang G., Zhu Z., Li W., Chai Y., Lou Z. Metabonomic profiles delineate the effect of traditional Chinese medicine sini decoction on myocardial infarction in rats. PLoS ONE 2012, 7:e34157.
14. Wang X., Zhang A., Wang P., Sun H., Wu G., Sun W., Lv H., Jiao G., Xu H., Yuan Y. Metabolomics coupled with proteomics advancing drug discovery toward more agile development of targeted combination therapies. Mol. Cell. Proteomics 2013, 12:1226-1238.
15. Lindon J.C., Holmes E., Nicholson J.K. Metabonomics techniques and applications to pharmaceutical research & development. Pharm. Res. 2006, 23:1075-1088.
16. Sreekumar A., Poisson L.M., Rajendiran T.M., Khan A.P., Cao Q., Yu J., Laxman B., Mehra R., Lonigro R.J., Li Y. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009, 457:910-914.
17. Wang M., Lamers R.J.A., Korthout H.A., van Nesselrooij J.H., Witkamp R.F., van der Heijden R., Voshol P.J., Havekes L.M., Verpoorte R., van der Greef J. Metabolomics in the context of systems biology: bridging traditional Chinese medicine and molecular pharmacology. Phytother. Res. 2005, 19:173-182.
18. Kanani H., Chrysanthopoulos P.K., Klapa M.I. Standardizing GC-MS metabolomics. J. Chromatogr. B 2008, 871:191-201.
19. Trygg J., Gullberg J., Johansson A.I., Jonsson P., Antti H., Marklund S.L., Moritz T., Extraction GC/MS analysis of the human blood plasma metabolome. Anal. Chem. 2005, 77:8086-8094.
20. Theodoridis G., Gika H.G., Wilson I.D. LC-MS-based methodology for global metabolite profiling in metabonomics/metabolomics. Trends Anal. Chem. 2008, 27:251-260.
21. Lu X., Zhao X., Bai C., Zhao C., Lu G., Xu G. LC-MS-based metabonomics analysis. J. Chromatogr. B 2008, 866:64-76.
22. Lin L., Huang Z., Gao Y., Yan X., Xing J., Hang W. LC-MS based serum metabonomic analysis for renal cell carcinoma diagnosis, staging, and biomarker discovery. J. Proteome Res. 2011, 10:1396-1405.
23. Soininen P., Kangas A.J., Würtz P., Tukiainen T., Tynkkynen T., Laatikainen R., Järvelin M.-R., Kähönen M., Lehtimäki T., Viikari J. High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst 2009, 134:1781-1785.
24. Bernini P., Bertini I., Luchinat C., Tenori L., Tognaccini A. The cardiovascular risk of healthy individuals studied by NMR metabonomics of plasma samples. J. Proteome Res. 2011, 10:4983-4992.
25. Xie G., Plumb R., Su M., Xu Z., Zhao A., Qiu M., Long X., Liu Z., Jia W. Ultra performance LC/TOF MS analysis of medicinal Panax herbs for metabolomic research. J. Sep. Sci. 2008, 31:1015-1026.
26. Xie G.X., Ni Y., Su M.M., Zhang Y.Y., Zhao A.H., Gao X.F., Liu Z., Xiao P.G., Jia W. Application of ultra-performance LC-TOF MS metabolite profiling techniques to the analysis of medicinal Panax herbs. Metabolomics 2008, 4:248-260.
27. Zelena E., Dunn W.B., Broadhurst D., Francis-McIntyre S., Carroll K.M., Begley P., O'Hagan S., Knowles J.D., Halsall A., Wilson I.D. Development of a robust and repeatable UPLC-MS method for the long-term metabolomic study of human serum. Anal. Chem. 2009, 81:1357-1364.
28. Want E.J., Wilson I.D., Gika H., Theodoridis G., Plumb R.S., Shockcor J., Holmes E., Nicholson J.K. Global metabolic profiling procedures for urine using UPLC-MS. Nat. Protoc. 2010, 5:1005-1018.
29. Gaballa M.A., Goldman S. Ventricular remodeling in heart failure. J. Card. Fail. 2002, 8:S476-S485.
30. Wang J., Liu X., Ren B., Rupp H., Takeda N., Dhalla N.S. Modification of myosin gene expression by imidapril in failing heart due to myocardial infarction. J. Mol. Cell. Cardiol. 2002, 34:847-857.
31. Hearse D.J., Sutherland F.J. Experimental models for the study of cardiovascular function and disease. Pharmacol. Res. 2000, 41:597-603.
32. Xia J., Mandal R., Sinelnikov I.V., Broadhurst D., Wishart D.S. MetaboAnalyst 2.0-a comprehensive server for metabolomic data analysis. Nucleic Acids Res. 2012, 40:W127-W133.
33. Stanley W.C. Myocardial energy metabolism during ischemia and the mechanisms of metabolic therapies. J. Cardiovasc. Pharmacol. Ther. 2004, 9:S31-S45.
34. Wang X., Su M., Qiu Y., Ni Y., Zhao T., Zhou M., Zhao A., Yang S., Zhao L., Jia W. Metabolic regulatory network alterations in response to acute cold stress and ginsenoside intervention. J. Proteome Res. 2007, 6:3449-3455.
35. Lionetti V., Stanley W.C., Recchia F.A. Modulating fatty acid oxidation in heart failure. Cardiovasc. Res. 2011, 90:202-209.
36. Lopaschuk G.D., Ussher J.R., Folmes C.D., Jaswal J.S., Stanley W.C. Myocardial fatty acid metabolism in health and disease. Physiol. Rev. 2010, 90:207-258.
37. Staiger H., Staiger K., Stefan N., Wahl H.G., Machicao F., Kellerer M., Häring H.-U. Palmitate-induced interleukin-6 expression in human coronary artery endothelial cells. Diabetes 2004, 53:3209-3216.
38. Wanten G.J., Naber A.H. Cellular and physiological effects of medium-chain triglycerides. Mini Rev. Med. Chem. 2004, 4:847-857.
39. Caffier G., Pfeiffer C. Effect of free fatty acids on the heart: effects of nonanoic acid on contractility and postextrasystolic potentiation in the rat papillary muscle. Acta Biol. Med. Ger. 1977, 36:1077-1084.
40. Yamori Y., Liu L., Ikeda K., Miura A., Mizushima S., Miki T., Nara Y. Distribution of twenty-four hour urinary taurine excretion and association with ischemic heart disease mortality in 24 populations of 16 countries: results from the WHO-CARDIAC study. Hypertens. Res. 2001, 24:453-457.
41. Yamori Y., Liu L., Mizushima S., Ikeda K., Nara Y. Male cardiovascular mortality and dietary markers in 25 population samples of 16 countries. J. Hypertens. 2006, 24:1499-1505.
42. Gamagedara S., Shi H., Ma Y. Quantitative determination of taurine and related biomarkers in urine by liquid chromatography-tandem mass spectrometry. Anal. Bioanal. Chem. 2012, 402:763-770.
43. Laine P., Kaartinen M., Penttilä A., Panula P., Paavonen T., Kovanen P.T. Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery. Circulation 1999, 99:361-369.
44. Tripathi P., Misra M. Therapeutic role of l-arginine on free radical scavenging system in ischemic heart diseases. Indian J. Biochem. Biophys. 2009, 46:498-502.
45. Tripathi P., Pandey S. l-Arginine attenuates oxidative stress condition during cardiomyopathy. Indian J. Biochem. Biophys. 2013, 50:99-104.
46. Itoh Y., Ezawa A., Kikuchi K., Tsuruta Y., Niwa T. Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production. Anal. Bioanal. Chem. 2012, 403:1841-1850.
47. Kikuchi K., Itoh Y., Tateoka R., Ezawa A., Murakami K., Niwa T. Metabolomic search for uremic toxins as indicators of the effect of an oral sorbent AST-120 by liquid chromatography/tandem mass spectrometry. J. Chromatogr. B 2010, 878:2997-3002.
48. Jiang P., Dai W., Yan S., Chen Z., Xu R., Ding J., Xiang L., Wang S., Liu R., Zhang W. Biomarkers in the early period of acute myocardial infarction in rat serum and protective effects of Shexiang Baoxin Pill using a metabolomic method. J. Ethnopharmacol. 2011, 138:530-536.